UpdatesPress Release
Sai Life Sciences reported strong Q3FY26: Revenue +27% to ₹556 Cr, EBITDA +54% to ₹191 Cr, PAT +86% to ₹100 Cr.
Sai Life Sciences LimitedSAILIFE · Filed with the exchange
Nine-month results also robust.
Company invested ₹405 Cr in capex, advancing AI and technology for future CRDMO growth.
No comments yet. Be the first.